Recce Pharmaceuticals Ltd (RCE) - Cash Flow Conversion Efficiency

Latest as of June 2026: -0.020x

Based on the latest financial reports, Recce Pharmaceuticals Ltd (RCE) has a cash flow conversion efficiency ratio of -0.020x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$341.10K ≈ $241.35K USD) by net assets (AU$-16.72 Million ≈ $-11.83 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Recce Pharmaceuticals Ltd stock valuation for the company's overall valuation and market capitalisation.

Recce Pharmaceuticals Ltd - Cash Flow Conversion Efficiency Trend (2014–2026)

This chart illustrates how Recce Pharmaceuticals Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Recce Pharmaceuticals Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Recce Pharmaceuticals Ltd ranked by their cash flow conversion efficiency. Explore Recce Pharmaceuticals Ltd cash earnings quality to measure how well operating cash flow supports reported net income.

Company	Cash Flow Conversion Efficiency
Samchem Holdings Bhd KLSE:5147	0.099x
Best Agrolife Limited NSE:BESTAGRO	N/A
FALCON METALS LTD F:E47	N/A
Gateway Real Estate AG XETRA:GTY	-0.048x
Fortune Minerals Limited TO:FT	0.132x
Shalimar Paints Limited NSE:SHALPAINTS	-0.010x
Cayman Engley Industrial Co TW:2239	0.033x
Comet Ridge Ltd AU:COI	-0.023x

Annual Cash Flow Conversion Efficiency for Recce Pharmaceuticals Ltd (2014–2026)

The table below shows the annual cash flow conversion efficiency of Recce Pharmaceuticals Ltd from 2014 to 2026. View RCE live share price for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2026-06-30	AU$-16.72 Million ≈ $-11.83 Million	AU$-9.89 Million ≈ $-7.00 Million	0.592x	-91.17%
2025-06-30	AU$-3.05 Million ≈ $-2.16 Million	AU$-20.44 Million ≈ $-14.46 Million	6.698x	+390.36%
2024-06-30	AU$-9.52 Million ≈ $-6.74 Million	AU$-13.01 Million ≈ $-9.20 Million	1.366x	-72.13%
2023-06-30	AU$-2.59 Million ≈ $-1.83 Million	AU$-12.69 Million ≈ $-8.98 Million	4.901x	+647.26%
2022-06-30	AU$10.06 Million ≈ $7.12 Million	AU$-9.01 Million ≈ $-6.38 Million	-0.896x	-133.73%
2021-06-30	AU$20.50 Million ≈ $14.51 Million	AU$-7.86 Million ≈ $-5.56 Million	-0.383x	+76.73%
2020-06-30	AU$2.31 Million ≈ $1.64 Million	AU$-3.81 Million ≈ $-2.69 Million	-1.646x	-125.56%
2019-06-30	AU$-405.60K ≈ $-286.99K	AU$-2.61 Million ≈ $-1.85 Million	6.440x	+358.34%
2018-06-30	AU$694.91K ≈ $491.70K	AU$-1.73 Million ≈ $-1.23 Million	-2.493x	+41.10%
2017-06-30	AU$590.14K ≈ $417.56K	AU$-2.50 Million ≈ $-1.77 Million	-4.233x	-825.16%
2016-06-30	AU$3.51 Million ≈ $2.49 Million	AU$-1.61 Million ≈ $-1.14 Million	-0.458x	-628.29%
2015-06-30	AU$4.71 Million ≈ $3.34 Million	AU$-296.14K ≈ $-209.54K	-0.063x	+69.36%
2014-06-30	AU$-55.74K ≈ $-39.44K	AU$11.43K ≈ $8.09K	-0.205x	--

About Recce Pharmaceuticals Ltd

AU:RCE Australia Biotechnology

Market Cap

$70.31 Million

AU$99.38 Million AUD

Market Cap Rank

#20684 Global

#697 in Australia

Share Price

AU$0.33

Change (1 day)

-4.41%

52-Week Range

AU$0.32 - AU$0.71

All Time High

AU$1.68